Janux Therapeutics (NASDAQ:JANX) Rating Increased to Strong-Buy at TD Cowen

Posted by Francis Steltz on Aug 25th, 2026

Janux Therapeutics (NASDAQ:JANX – Get Free Report) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a research report on Friday, August 7th. Piper Sandler reduced their price target on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, May 8th. JonesTrading decreased their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. Truist Financial reiterated a “buy” rating and set a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.46.

View Our Latest Research Report on JANX

Janux Therapeutics Stock Performance

Shares of JANX opened at $18.60 on Monday. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The business’s 50 day moving average price is $15.76 and its two-hundred day moving average price is $14.67. The firm has a market cap of $1.14 billion, a PE ratio of -11.34 and a beta of 2.50.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. Research analysts predict that Janux Therapeutics will post -1.76 EPS for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by insiders.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nano Cap New Millennium Growth Fund L P acquired a new position in Janux Therapeutics during the fourth quarter worth $34,000. Versant Capital Management Inc grew its holdings in shares of Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after buying an additional 784 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Janux Therapeutics during the fourth quarter valued at about $51,000. Osaic Holdings Inc. increased its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares in the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Janux Therapeutics by 2,290.0% during the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock worth $84,000 after acquiring an additional 5,267 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.